Full Extent Of Clinical Trial Damage May Be Unknown Until Pandemic Ends, CBER’s Peter Marks Says

 
• By Derrick Gingery
A rack containing empty test tubes in a microbiology lab.
Virtual clinical trial design features may continue after the pandemic and allow more patient participation, CBER Director Peter Marks said. • Source: Shutterstock

More from Clinical Trials

More from R&D